HYTN Secures Strategic Supply Agreements and Qualifies4000kg of Cannabis for German Market
Source: HYTN Innovations Inc.
March 28, 2025 20:00 ET
HYTN Secures Strategic Supply Agreements and Qualifies
4000kg of Cannabis for German Market
VANCOUVER, British Columbia, March 28, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or the "Company"), a leader in pharmaceutical-grade
cannabis manufacturing, is pleased to announce it has entered into strategic supply agreements
(the “Agreements”) and successfully completed vendor qualication with two cannabis cultivators
under its Good Manufacturing Practice (GMP) system qualifying a minimum of 4000 kg of cannabis
for the German market. This milestone builds on HYTN’s recent announcements outlining its
strategic transition into international pharmaceutical sales, including partnerships with SNDL Inc
(SNDL) and 4C Labs, and further strengthens its manufacturing scope, positioning the Company for
continued global expansion.
The Agreements, which were entered into in February 2025, were subject to HYTN’s rigorous
qualication process through which the Company conducted comprehensive site audits, quality
control evaluations, and veried compliance with Good Agricultural and Collection Practices (GACP)
to ensure alignment with German pharmacopeia standards. These Agreements establish strict
product specications, testing protocols, and pricing structures, ensuring compliance with stringent
microbiological limits and non-irradiation requirements while securing a reliable and consistent
cannabis supply for Germany. The two cultivators which have been qualied in HYTN’s system for
the German market are Klonetics Plant Science Inc. and another Kelowna company which has
requested non-disclosure.
With qualication complete, the approved cultivators will commence production, focusing on high-
potency cultivars specically tailored for German patient needs HYTN’s GMP-certication ensures
that all cannabis destined for Germany will adhere to the highest pharmaceutical standards,
meeting the country's exacting regulatory requirements.
"With global demand for GMP-certied cannabis increasing, HYTN remains committed to
partnering with the most qualied cultivators to ensure seamless integration into international
medical markets," said Jason Broome, HYTN Chief Operating Ofcer. He added, “We are proud to
support patient access to premium medical cannabis in Germany and look forward to establishing
HYTN as a preferred partner for pharmaceutical-grade cannabis in Europe."
Germany’s medical cannabis sector is experiencing rapid growth, driven by increasing patient
adoption, expanded physician prescribing, and broadening pharmacy distribution. In Q3 2024
alone, Germany imported 20,000 kilograms of medical cannabis. This was more than double the
quarterly average prior to the April 2024 regulatory reforms and demonstrated surging demand for
compliant pharmaceutical cannabis products1.
HYTN anticipates the arrival of the initial cultivation batches for GMP processing in Q2 2025, with
the rst shipments to Germany expected in late Q2 2025.
1. Johnny Green, "Legal Medical Cannabis Imports Surged In Q3 In Germany" (2024)
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and psychotropic compounds, including
cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming
a premier provider of these products across all federally regulated markets. The Company
accomplishes this by strategically identifying market opportunities and effectively bringing
innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that
a manufactured product is safe for human consumption or use. Many countries have legislated that
manufacturers follow GMP procedures and create their own GMP guidelines that correspond with
their legislation.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents
of this press release.
Certain information contained herein constitutes forward-looking information that involves risks
and uncertainties. Readers are cautioned not to place undue reliance on forward-looking
statements, including, but not limited to, statements regarding the expected outcome of qualifying
cannabis for the German Market, the Company’s ability to distribute products in new markets or in
larger quantities in existing markets, and the Company’s ability to maintain regulatory and
licensing requirements. Factors that could cause actual results to vary from forward-looking
statements or may affect the operations, performance, development, and results of the Company’s
business include, among other things: the Company’s inability to successfully obtain new licenses
and certications, or to amend existing ones, and its inability to distribute products into new
markets or in increasing quantities in existing markets, or to continue to maintain licensing and
certication standards; changes in regulatory requirements affecting product registration or
distribution; shifts in market demand for cannabis beverages; competitive factors within the
industry; and general economic and business conditions. Any statements that are not statements of
historical fact are deemed to be forward-looking statements. The forward-looking statements
contained in this news release are made as of the date of this news release, and, except to the
extent required by applicable law, the Company assumes no obligation to update or revise forward-
looking statements made herein or otherwise, whether because of new information, future events,
or otherwise. The forward-looking statements contained in this news release are expressly qualied
by this cautionary note.
